T-Cell therapy

BIOLOGICAL2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, David Avigan

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseHER2-positive Breast Cancer

Phase 1

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

SuspendedNCT05378464

H. Lee Moffitt Cancer Center and Research InstituteHER2-positive Breast Cancer

Start: 2022-05-31End: 2026-12-01Target: 28Updated: 2026-09-15

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

RecruitingNCT07374029

David AviganAcute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse

Start: 2026-02-12End: 2030-10-01Target: 30Updated: 2026-05-05

Related Papers

A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).

Journal of Clinical Oncology2024-06-011 citations

Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).

Journal of Clinical Oncology2023-06-013 citations

645 Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)

Regular and Young Investigator Award Abstracts2022-11-01